News | January 15, 2008

JMAR Technologies Releases BioSentry Designed For High-Purity Water Applications

New System to Be Tested in Pharmaceutical Manufacturing Application

San Diego, CA — JMAR Technologies, Inc., a leading developer of advanced laser, photonics and detection technologies, has announced a new release of its flagship sensor product, the BioSentry™, which has been engineered specifically for use in pharmaceutical manufacturing and other high-purity water applications.

BioSentry™ is a water monitoring system that provides early contamination warning from waterborne microorganisms. Whereas current water monitoring depends on grab sampling of water and time-consuming lab analysis, BioSentry uses laser-based technology to provide continuous, on-line, real-time monitoring of harmful bacteria. Initially, BioSentry targeted applications in homeland security, the beverage industry, and municipal drinking water utilities. With recent system enhancements, the BioSentry can now meet the stringent requirements of high-purity water applications in such industries as pharmaceutical, personal health care and semiconductor manufacturing.

Upgrades to the BioSentry include:

  • High temperature compatibility for water for injection (WFI) and sanitation requirements
  • Use of pharmaceutical-grade materials including a 316L stainless steel flow cell
  • Automatic flow control
  • Auto-sanitization
The new system is currently being installed for testing at a major U.S. pharmaceutical company as part of their Process Analytical Technology (PAT) program. PAT is a system for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes of in-process materials with the goal of ensuring final product quality1.

Commenting on the new product enhancements, David McCarty, Vice President for JMAR's Sensor Products Group, stated, "The new release of the BioSentry is a major milestone in our product development. Not only have we broadened the scope of markets and applications we can now address, but our core system has evolved to be more robust and easier to maintain."

"These developments in the BioSentry product line are evidence of JMAR's determination and ability to design and deploy application-specific solutions," said Dr. Neil Beer, President and CEO of JMAR. "I believe acceptance of the BioSentry in the pharmaceutical industry will open doors to a host of high-purity water applications, resulting in increased sales and greater market penetration."

1 Reference FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Process Analytical Technology (PAT) Initiative

SOURCE: JMAR Technologies, Inc.